- Investing Ideas
- U.K. Pharmaceuticals & Biotech Pure Equity Growth
U.K. Pharmaceuticals & Biotech Pure Equity Growth
Results
10
Companies that has zero debt on their balance sheet and is forecast to grow at an exponential rate in the future.
10 companies
Corcept Therapeutics
Market Cap: US$10.0b
A biopharmaceutical company, engages in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic, and neurologic disorders in the United States.
0I3Q
US$121.86
7D
26.5%
1Y
73.0%
Camurus
Market Cap: SEK 37.2b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
0RD1
SEK 623.50
7D
1.4%
1Y
-9.1%
Camurus
Market Cap: SEK 37.2b
A biopharmaceutical company, develops and commercializes medicines for severe and chronic diseases in Europe, Africa, the Middle East, North America, and Asia.
CAMXS
SEK 625.00
7D
1.5%
1Y
-10.7%
BioArctic
Market Cap: SEK 28.7b
Develops biological drugs for patients with central nervous system disorders in Sweden.
BIOABS
SEK 297.40
7D
0%
1Y
n/a
BioArctic
Market Cap: SEK 28.8b
Develops biological drugs for patients with central nervous system disorders in Sweden.
0RV2
SEK 324.00
7D
6.3%
1Y
51.6%
Bonesupport Holding
Market Cap: SEK 14.6b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
0RQO
SEK 220.60
7D
7.8%
1Y
-34.9%
Bonesupport Holding
Market Cap: SEK 14.6b
An orthobiologics company, develops and commercializes injectable bio-ceramic bone graft substitutes in the United States, Europe, and internationally.
BONEXS
SEK 219.70
7D
0%
1Y
-35.2%
Kuros Biosciences
Market Cap: CHF 928.9m
Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.
0RHR
CHF 23.37
7D
14.4%
1Y
-22.9%
Kuros Biosciences
Market Cap: CHF 928.9m
Engages in the commercialization and development of biologic technologies for musculoskeletal care in the United States of America, the European Union, and internationally.
KURNz
CHF 23.56
7D
15.3%
1Y
-21.7%
BioPorto
Market Cap: DKK 599.1m
An in-vitro diagnostics company, focuses on developing biomarker tests to help clinicians detect the kidney injury in critically ill patients at earlier stage in Denmark, rest of Europe, North America, and Asia.
0JJM
DKK 1.29
7D
0%
1Y
n/a